Aging Trial Endpoints: A Role-Based Interpretation Framework Without False Equivalence
An endpoint label tells readers where a measure sits in a trial plan. It does not, by itself, tell them whether the measure is clinically important, whether the…
LongevityNext
Research Notes and Articles
From Preclinical Promise to Human Evidence: How to Read a Longevity Translation Claim
“Translated to humans” can mean exposure, target engagement, biomarker movement, short-term safety or clinical benefit. This evidence-led explainer separates those claims and shows what each result supports—and which…
Aging as Loss of Resilience: The Framework Behind Healthspan Science
Move from lifespan to resilience; explain why older biological systems fail to recover from stressors even before disease appears. The piece keeps the focus on evidence, commercial logic,…
Autophagy Is Becoming a Drug Target. The Hard Part Is Measuring It
Autophagy is central to aging biology, but proving target engagement and clinical benefit in humans remains difficult. The piece keeps the focus on evidence, commercial logic, and what…
Resilience Endpoints: Why Recovery May Matter More Than Biological Age
Vaccine response, post-surgery recovery, infection recovery, exercise adaptation, and stress-response tests as practical geroscience endpoints. The piece keeps the focus on evidence, commercial logic, and what would make…
Why Extracellular Matrix Changes Are Becoming Harder to Ignore in Aging Science
Explain tissue stiffness, matrix remodeling, fibrosis, and organ mechanics as part of the next phase of aging biology. The piece keeps the focus on evidence, commercial logic, and…
The Difference Between Prevention, Optimization, and Treatment in Longevity Medicine
Use the backup evergreen idea to replace a duplicate disease-claim topic already published. The piece keeps the focus on evidence, commercial logic, and what would make the claim…
Why Model Organisms Still Matter – and Where They Mislead Longevity Science
Use the backup evergreen idea to replace a duplicate calendar topic already published. The piece keeps the focus on evidence, commercial logic, and what would make the claim…
What Would an Aging Indication Actually Require?
Explain what regulators would need: a defined population, validated endpoints, benefit-risk logic, trial precedent, and a way to avoid turning aging itself into a vague commercial label. The…
Why Regulators Still Don’t Approve “Aging” — and What Longevity Startups Do Instead
For a field built on the idea that aging is the biggest upstream driver of chronic disease, the obvious commercial question is also the most frustrating one: if…